China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Three-Dimensional Reconstruction and Accurate Quantitative Study of Posterior Globe Mor... Read More
China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'The impact of inflammatory index on postoperative delirium in aortic dissection'. The f... Read More
China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and Safety of Accelerated Combined Electromagnetic Therapy for Rapid Intervent... Read More
China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Single-Arm, Phase II Clinical Study of Ivonescimab Combined with Chemotherapy for the... Read More
China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Objective Assessment of Subjective Tinnitus Based on Non-Invasive Brain–Computer Interf... Read More
China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Low-dose aspirin for the prevention of tumor recurrence and metastasis after liver tran... Read More
China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Prospective, Multicenter, Randomized Controlled, Non-Inferiority Clinical Trial Evalu... Read More
China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Four-Week Mindfulness Intervention for Parents of Middle and High School Students in ... Read More
China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'One-step Rehydration Thawing Method in Frozen Embryo Transfer: A pragmatic randomized c... Read More
China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advance... Read More